ResMed | RMD - Current Liabilities


ResMed reported $1.35B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Ansell USD 468.9M 53.1M Dec/2025
Artivion USD 92.7M 8.86M Mar/2026
AtriCure USD 73.19M 8.33M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Cochlear AUD 558.9M 43.4M Dec/2025
Cooper Companies USD 1.8B 209M Mar/2026
CSL USD 4.61B 207M Dec/2025
Dexcom USD 2.22B 81.3M Mar/2026
Edwards Lifesciences USD 1.41B 404.7M Mar/2026
Fisher Paykel Healthcare NZD 497.8M 26.5M Jun/2026
Globus Medical USD 482.46M 16.04M Mar/2026
Haemonetics USD 282.6M 257.27M Mar/2026
Idexx Laboratories USD 1.3B 151.04M Mar/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 687.5M 7.4M Mar/2026
Integra LifeSciences USD 346.85M 109.14M Mar/2026
Intuitive Surgical USD 2.51B 3.2M Mar/2026
Medtronic USD 9.5B 440M Dec/2025
Philips EUR 7.43B 78M Mar/2026
Ramsay Health Care AUD 3.95B 514.2M Dec/2025
ResMed USD 1.35B 103.1M Mar/2026
Sigma Healthcare AUD 1.7B 1.33B Dec/2025
Sonic Healthcare AUD 2.23B 92.84M Dec/2024
Steris USD 1.14B 222.7M Mar/2026
Teleflex USD 728.05M 33.98M Mar/2026
Thermo Fisher Scientific USD 14.62B 568M Mar/2026